文献速递炎症性肠病

非肿瘤坏死因子拮抗剂生物制剂联合免疫调节剂治疗炎症性肠病无疗效获益:一项Meta分析

No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-07-03

该系统检索截至2019年7月31日的33项研究(6项随机对照试验和27项队列研究),比较维多珠单抗或乌司奴单抗联合免疫调节剂与单药治疗的疗效与安全性。结果显示联合治疗在临床结局、内镜改善及不良事件方面均无显著获益,诱导或维持缓解均不优于单药治疗。

要点

  • 维多珠单抗联合免疫调节剂与单药相比临床结局无显著差异(OR 0.84,95%CI 0.68-1.05)。
  • 乌司奴单抗联合免疫调节剂与单药相比临床结局无显著差异(OR 1.1,95%CI 0.87-1.38)。
  • 联合治疗未增加维多珠单抗治疗期间的不良事件(OR 1.17,95%CI 0.75-1.84)。

核心结论

  • 在炎症性肠病患者中,维多珠单抗或乌司奴单抗联合免疫调节剂在诱导或维持缓解方面均不优于单药治疗。

研究设计与样本

  • 系统检索截至2019年7月31日的文献,纳入33项研究(6项随机对照试验和27项队列研究)的炎症性肠病患者,接受维多珠单抗或乌司奴单抗治疗。

主要发现

  • 维多珠单抗联合治疗与单药相比临床结局无显著差异(16项研究:OR 0.84,95%CI 0.68-1.05;I²=13.9%;Q检验P=0.17)。
  • 乌司奴单抗联合治疗与单药相比临床结局无显著差异(15项研究:OR 1.1,95%CI 0.87-1.38;I²=11%;Q检验P=0.28)。
  • 维多珠单抗联合治疗与单药相比内镜结局无显著差异(3项研究:OR 1.13,95%CI 0.48-2.68;I²=0;Q检验P=0.96)。
  • 乌司奴单抗联合治疗与单药相比内镜结局无显著差异(2项研究:OR 0.58,95%CI 0.21-1.16;I²=47%;Q检验P=0.17)。
  • 维多珠单抗治疗期间联合治疗与单药相比不良事件无显著增加(4项研究:OR 1.17,95%CI 0.75-1.84;I²=0;Q检验P=0.110)。

关键数值与推荐

  • 维多珠单抗联合免疫调节剂与单药相比临床结局OR 0.84(95%CI 0.68-1.05),未达统计学显著。
  • 乌司奴单抗联合免疫调节剂与单药相比临床结局OR 1.1(95%CI 0.87-1.38),未达统计学显著。
  • 维多珠单抗联合治疗与单药相比内镜结局OR 1.13(95%CI 0.48-2.68),未达统计学显著。
  • 乌司奴单抗联合治疗与单药相比内镜结局OR 0.58(95%CI 0.21-1.16),未达统计学显著。
  • 维多珠单抗治疗期间联合治疗与单药相比不良事件OR 1.17(95%CI 0.75-1.84),未达统计学显著。

临床怎么用

  • 原文结论为联合治疗在诱导或维持缓解方面不优于单药治疗,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is debate over whether patients with inflammatory bowel diseases (IBD) treated with biologics that are not tumor necrosis factor antagonists (such as vedolizumab or ustekinumab) should receive concomitant treatment with immunomodulators. We conducted a meta-analysis to compare the efficacy and safety of concomitant immunomodulator therapy vs vedolizumab or ustekinumab monotherapy. METHODS: In a systematic search of publications, through July 31, 2019, we identified 33 studies (6 randomized controlled trials and 27 cohort studies) of patients with IBD treated with vedolizumab or ustekinumab. The primary outcome was clinical benefit, including clinical remission, clinical response, or physician global assessment in patients who did vs did not receive combination therapy with an immunomodulator. Secondary outcomes were endoscopic improvement and safety. We performed random-effects meta-analysis and estimated odds ratio (OR) and 95% CIs. RESULTS: Overall, combination therapy was not associated with better clinical outcomes in patients receiving vedolizumab (16 studies: OR, 0.84; 95% CI, 0.68-1.05; I2=13.9%; Q test P = .17) or ustekinumab (15 studies: OR, 1.1; 95% CI, 0.87-1.38; I2 = 11%; Q test P = .28). Results were consistent in subgroup analyses, with no difference in clinical remission or response in induction vs maintenance studies or in patients with Crohn's disease vs ulcerative colitis in studies of vedolizumab. Combination therapy was not associated with better endoscopic outcomes in patients receiving vedolizumab (3 studies: OR, 1.13; 95% CI, 0.48-2.68; I2 = 0; Q test P=.96) or ustekinumab (2 studies: OR, 0.58; 95% CI, 0.21-1.16; I2 = 47%; Q test P = .17). Combination therapy was not associated with an increase in adverse events during vedolizumab therapy (4 studies: OR, 1.17; 95% CI, 0.75-1.84; I2 = 0; Q test P = .110). CONCLUSIONS: In a meta-analysis of data from studies of patients with IBD, we found that combining vedolizumab or ustekinumab with an immunomodulator is no more effective than monotherapy in induction or maintenance of remission.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Yzet C, Diouf M, Singh S, et al. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32629124. doi:10.1016/j.cgh.2020.06.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。